PATENT CLAIM ANALYSIS

Application Number: 16204166
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-07
Patent Classification: ["544", "242000"]

Abstract:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Claim (Index 11):
A pharmaceutical composition, comprising a compound or a combination of compounds according to  claim 1 , or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 98.0
- Lexical Diversity: 1.73016
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15209150', '15088517', '15216124', '16194608', '15421777']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8119986613657776
- 35 USC 102 Novelty (BERT): 0.5517635557969872
- Combined Prediction Score: 0.7859751508088986
- Mean Citation Score: 392.076462
- Max Citation Score: 423.04852
- Similarity Product: 403.485507449255

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test